X-ACKT · XPF-010-303
Public neurological clinical research study information. Check the current recruitment status in the live Wix study record.
A Randomized, Double-blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures. Eudra CT: 2022-502286-16-00
Sponsor: Xenon Pharmaceuticals
Phase: III
Area: Epilepsy